Syngene International Ltd. · NSE:SYNGENE
Syngene International — Q3 FY22 Earnings Presentation
43 slides from Syngene International's earnings presentation, Jan 19, 2022
Slide 1: Stock exchange cover letter
Ref: Syn/CS/SE/IP/2021-22/Jan/07 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com January 19, 2022 T
Slide 2: Investor Presentation January 2022
Investor Presentation January 2022 Strictly confidential and privileged
Slide 3: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 4: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 5: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 6: Q3 performance highlights
Q3 performance highlights All figures in Rs. Mn unless otherwise specified Operating Highlights Q3 FY22 Financial Highlights ▪ Revenue from Operations growth led by Discovery Services and • Revenue from operations increased by 10% year-on-year Dedicated Centers with sustained performance in other di
Slide 7: Q3 FY22 Financial Performance
Q3 FY22 Financial Performance All figures in Rs. Mn unless otherwise specified P&L Summary Q3 FY22 Q3 FY21 YoY Change Q3 FY22 performance: Revenue from operations 6,414 5,845 10% Total Revenue 6,543 6,016 9% • Revenue from operations increased by 10% for the quarter compared to the previous year whi
Slide 8: FY22 Guidance updated from mid teen revenue growth to high teen growth
FY22 Guidance updated from mid teen revenue growth to high teen growth FY22 Guidance given in 9 months Actual Updated guidance for FY22 April ’21 Revenue from operations growth Mid teen growth 21% High teen growth Reported EBITDA Margin 30% 31% Slightly above 30% Profit before Tax No guidance 21% Mi
Slide 9: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 10: Putting science to work: Who we are and what we do
Putting science to work Who we are and what we do ▪ Offering integrated research, development and manufacturing services to take projects from early discovery to commercial supply ▪ Working with clients from around the world to find solutions to their scientific challenges for small and large molecu
Slide 11: Syngene key facts and figures
Syngene key facts and figures All figures are as on March 31, 2021, unless otherwise specified 15 2 Mn sq. ft. 400+ collaborations 450+ of World class active with top 20 Patents infrastructure, clients pharmaceutical held with qualified to meet companies clients international standards Rs. 35,634 Mn
Slide 12: The Syngene advantage
The Syngene advantage Integrated service International 25+ years Flexible and Experienced Talented & provider accreditations of unparalleled varied business in successfully experienced offering end-to-end USFDA,OHSAS 18001, GLP, experience models managing large scientific and drug discovery, cGMP, A
Slide 13: Our experience spans multiple industry segments and partnerships with global leaders
Our experience spans multiple industry segments and partnerships with global leaders across the world Clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs) Leading China based crop protection company Global food and beverage company Large Japanese chemical com
Slide 14: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 15: Biocon Group and Syngene
Biocon Group and Syngene • Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company • Syngene, a subsidiary of Biocon Limited, was established in 1993 as India’s first Contract Research Organization - Company has 25 years plus of unparalleled experience in novel molecu
Slide 16: Syngene – 27 years of solving complex R&D problems for our clients
Syngene – 27 years of solving complex R&D problems for our clients A Global CRO/CDMO IP Position Quality Focus • Integrated Drug Discovery, Development and • IP can be fully assigned to clients • Quality driven organization Manufacturing service provider • Strong track record of Data • Excellent tra
Slide 17: Our journey so far
Our journey so far All figures in Rs. Mn unless otherwise specified Foundation Globalization and strategic collaboration Continued investments and growth • Operations started • Expanded into formulations development • Crossed annual turnover of Rs. 20 Billion in 2020 • Expansion of R&D Lab • Contrac
Slide 18: Strong track record of growth and profitability
Strong track record of growth and profitability All figures in Rs. Mn unless otherwise specified Client Footprint (%) ▪ Growth driven by increase in sales from existing clients and acquisition of Client Base 4% USA new clients 5% 5% FY21 402 Europe ▪ Strategy to extend client relationship over a lon
Slide 19: Multiple levers for growth going ahead
Multiple levers for growth going ahead Expand/Extend Existing Clients Capacity Expansion - High service integration - Consistent investment - Dedicated centers model - FTE services, manufacturing, formulation, biologics, stability Engage New Clients - Tailored service offerings and Client Capacity d
Slide 20: Our divisions
Our divisions Discovery Development Manufacturing Dedicated Services Services Services R&D Centers Engaged in early-stage Engaged in activities from pre- Engaged in the Dedicated R&D facilities for research, from target clinical to clinical trials, manufacturing of small and strategic clients provid
Slide 21: Our collaboration models
Our collaboration models 1 2 3 4 5 Dedicated R&D Labs FTE FFS Outcome based model Risk-reward with SLA • Dedicated scientific and • Pre-defined numbers of • Client collaboration to • Offer services based on • Across a portfolio of support teams work scientific personnel from deliver agreed services
Slide 22: Our dedicated R&D centers exemplify the success of our long-term strategic alliances
Our dedicated R&D centers exemplify the success of our long-term strategic alliances >600 scientists c. 200 scientists c.170 Scientists 300,000+ sq. ft. laboratory space 70,000 sq. ft. laboratory space 60,000 sq. ft. laboratory space Largest R&D Center in Asia for BMS (est.d Dedicated R&D Center in
Slide 23: Our end-to-end platform enables us to be a one-stop-shop
Our end-to-end platform enables us to be a 'one-stop-shop' for discovery, development and manufacturing (small and large molecules) Discovery Development Manufacturing Chemistry Drug Substance Small Molecules Large Clinical Supplies Molecules Drug Product Biology Integrated Drug Substance – HPAPI An
Slide 24: Discovery Services: From target to a drug candidate
Discovery Services: From target to a drug candidate Candidate Hit to lead Lead optimisation Development selection Candidate Candidate 5 Lead Selection Development Compounds^ Exploratory PK, Tox and Developability Assessment 20 Lead In-Vivo DMPK Profiling, Compounds^ CADD 500 Lead Generation of focus
Slide 25: Development Services
Development Services ▪ Encompass activities across multiple disciplines as a molecule moves from pre- clinical to clinical trials Preclinical Studies Drug ▪ Key activities include: product Dvpt. ▪ Drug substance development (process R&D and optimisation) Drug Substance ▪ Drug product development (pr
Slide 26: Manufacturing Services
Manufacturing Services Small Molecules • State-of-the-art cGMP (Current Good Manufacturing Practices) and GMP(Good Manufacturing Practice) facility to manufacture new chemical entities (NCEs) • Designed to support multi gram to 100s of kgs/ batch of Intermediates and APIs for clinical trials • New g
Slide 27: Backed by world class state of the art infrastructure
Backed by world class state of the art infrastructure HQ Campus – 90 Acres in Bangalore where most of Syngene’s capabilities are R&D Expansion: Genome housed today Valley, Hyderabad, India commenced operation in Aug 2019 Biologics Expansion: HQ Campus Biologics Manufacturing Plant Scale: Mammalian-
Slide 28: Agile and experienced workforce supported by continuous learning
Agile and experienced workforce supported by our commitment to continuous learning All figures are as on March 31, 2021, unless otherwise specified ~5,400 strong pool of employees Environment that engages our employees and enables them to grow 24% female employees vs 16% in FY16 Adapting to the new
Slide 29: Harnessing digitization and automation
Harnessing digitization and automation Generating reliable and retrievable data by using advanced technology platforms. Online management of specifications, Online document storage and Online Training Platform procedures, policies, checklist, manuals, BMR, issuance which tracks learner SMF, TTD, pro
Slide 30: Strategic Sourcing – agility and resilience that makes a difference
Strategic Sourcing – agility and resilience that makes a difference Our dedicated Strategic Sourcing professionals have the expertise and experience to work closely with our global supplier base to ensure timely delivery of supplies for smooth operations of the company, while ensuring strict adheren
Slide 31: Operational excellence is a way of life
Operational excellence is a way of life Black Belt Certification • Syngene rolled out Build capability the SQDECC* continuous improvement program Green Belt Certification organization-wide to engage all employees to improve Create culture of excellence operational efficiency (Function wise) White Be
Slide 32: Led by a globally experienced management team
Led by a globally experienced management team Management team Jonathan Hunt Dr. Mahesh Bhalgat Sibaji Biswas Ashu Tandon Sanjeev Sukumaran Managing Director and Chief Operating Officer Chief Financial Officer Chief Commercial Officer Chief Human Resources Officer Chief Executive officer Previous Ast
Slide 33: Advised by Our Board of Directors
Advised by Our Board of Directors Board of Directors Kiran Mazumdar Shaw Jonathan Hunt Dr. Carl Decicco Professor Catherine Rosenberg Vinita Bali Non-Executive Chairperson Managing Director and CEO Independent Director Non-Executive Director Independent Director Chairperson of Biocon Limited, ~30 ye
Slide 34: Committed to sustainability
Committed to sustainability All figures are as on March 31, 2021, unless otherwise specified Safety is at the heart of everything we do Committed to environmental protection Accredited with ISO 14001:2015 for its effective Accredited with ISO 45001:2018 for its Occupational Health Environment Manage
Slide 35: Our first ESG Summary report
Our first ESG Summary report is a step towards delivering a transparent account of our progress on financial and non-financial parameters The summary report has outlined the way we approach ESG across key dimensions of our business as stated below • Environmental Governance • Quality management syst
Slide 36: Industry recognition for scientific capability and best practices
We have consistently received industry recognition for our scientific capability and best practices • Bio-Excellence Award 2018 - At Bengaluru • CMO Leadership Award Winner 2020 - under • Dynamic Enterprise of the Year 2016 - Tech Summit, Bengaluru Categories: Capabilities, Compatibility, At the 9th
Slide 37: Proactively managing risks through our robust risk management framework
Proactively managing risks through our robust risk management framework Syngene has a risk management framework to identify, monitor, report and manage risk across the business. Every risk owner monitors and manages risks relevant to their area of responsibility. Executive Committee (EC) Board of Di
Slide 38: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 39: Q3 and 9M FY22 financial highlights
Q3 and 9M FY22 financial highlights All figures in Rs. Mn unless otherwise specified Particulars Q3 FY22 Q3 FY21 YoY Change Q2 FY22 QoQ change 9M FY22 9M FY21 YoY Change Revenue from Operations 6,414 5,845 10% 6,102 5% 18,461 15,257 21% Other Income 129 171 (25%) 129 - 381 462 (18%) Total Revenue 6,
Slide 40: FY21 financial highlights
FY21 financial highlights All figures in Rs. Mn unless otherwise specified Particulars FY21 FY20 YoY Change Revenue from operations (excl export incentives) 21,802 19,465 12% Balance Sheet Highlights Export incentives 41 654 (94%) Other Income 646 816 (21%) Total Revenue 22,489 20,935 7% As on 31st
Slide 41: Contents
Contents 1 Operating and Financial Highlights 2 Syngene – Putting Science to Work 3 Company and Business Overview 4 Financials 5 Shareholding and Share Information
Slide 42: Shareholding and Share Information
Shareholding and Share Information Syngene’s Shareholding Pattern* Syngene’s Share Information* NSE Ticker SYNGENE BSE Ticker 539268 1% Promoter & Market Cap (Rs. Mn) 2,48,454 29% Promoter Group % free-float 29% Public Free-float market cap (Rs. Mn) 71,729 Share Outstanding (Mn) 401 ESOP Trust 3M AD
Slide 43: Thank You
THANK YOU For more details www.syngeneintl.com • Visit www.syngeneintl.com • IR Contact: Krishnan G + 91 806 891 9807 investor@syngeneintl.com Putting Science to Work
Syngene International — Q3 FY22 Earnings Presentation on 6ix